Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALITHIOS: Long-term Extension Study of Ofatumumab in Relapsing Multiple Sclerosis
NCT03650114Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 37
01
Overview
Phase 3, open-label, single-arm trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Adverse Events at 8 years. Started Dec 2018; status: active, not recruiting.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03650114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650114.